Company Overview of Peloton Therapeutics, Inc.
Peloton Therapeutics, Inc., an early-stage cancer drug discovery and development company, engages in the development of oncology drugs. The company was incorporated in 2010 and is based in Dallas, Texas.
2330 Inwood Road
Dallas, TX 75235-7323
Founded in 2010
Key Executives for Peloton Therapeutics, Inc.
Compensation as of Fiscal Year 2017.
Peloton Therapeutics, Inc. Key Developments
Peloton Therapeutics, Inc. Initiates Patient Dosing in Phase 2 Study of PT2385 for Von Hippel-Lindau Disease-Associated Kidney Cancer
May 11 17
Peloton Therapeutics, Inc. announced the initiation of patient dosing in a Phase 2 study of PT2385, the Company’s investigational first-in-class small molecule drug targeting hypoxia-inducible factor 2a (HIF-2a), for patients with von Hippel-Lindau (VHL) disease-associated kidney cancer. The primary objective of the study is to assess the overall response rate (ORR) of VHL disease-associated clear cell renal cell carcinoma (ccRCC) tumors in untreated VHL patients who received PT2385. The study is being conducted in collaboration with the National Cancer Institute (NCI). PT2385 is a selective, orally active agent that blocks HIF-2a with potent anti-cancer activity in preclinical models of ccRCC. This open-label Phase 2 study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of PT2385 in patients with VHL disease who have at least one measurable VHL disease-associated ccRCC tumor (as defined by RECIST 1.1). PT2385 will be administered orally and treatment will be continuous unless there is disease progression. Changes in VHL disease-associated non-ccRCC lesions will also be evaluated.
Peloton Therapeutics, Inc. Appoints Mohammad Hirmand as Chief Medical Officer, Effective from May 1, 2017
Apr 3 17
Peloton Therapeutics, Inc. announced the appointment of Mohammad Hirmand, M.D., as Chief Medical Officer. Dr. Hirmand will assume his new role on the executive management team on May 1, 2017 and will lead the company’s clinical drug development forward. Dr. Hirmand most recently served as Chief Medical Officer at Medivation, where he played a vital role in advancing XTANDI (enzalutamide) through clinical trials that led to its approval by the U.S. Food and Drug Administration for the treatment of metastatic castration-resistant prostate cancer. His responsibilities also included the in-licensing and global clinical development of the poly ADP ribose polymerase inhibitor, talazoparib. Before Medivation, he was Senior Director of Clinical Development at Nuvelo, Inc., where he led the Clinical Operations, Clinical Data Management and Clinical Sciences/Medical Monitor staff. Prior to that, he served as Director of Oncology Development at SuperGen, Inc. and as Associate Director of Clinical Research at Amgen, Inc., where he led clinical development efforts for Tularik's oncology trials.
Peloton Therapeutics, Inc. Presents Clinical Data on First-In-Class Oral HIF-2a Inhibitor in Patients with Advanced Kidney Cancer
Jun 6 16
Peloton Therapeutics, Inc. presented first-in-human Phase 1 clinical data on its lead investigational candidate, PT2385, at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago is the first clinical stage antagonist of hypoxia inducible factor-2a (HIF-2a), a transcription factor implicated in the development and progression of kidney and other cancers. Patients with advanced clear cell renal cell carcinoma and at least one prior therapy with a VEGF inhibitor were treated with PT2385 to determine the recommended Phase 2 dose and evaluate safety, pharmacokinetics and pharmacodynamics. Twenty-six patients were enrolled in dose escalation and received PT2385 from 100 to 1,800 mg twice per day. Patients were heavily pretreated prior to study entry, with greater than 50% having four or more prior therapies. Exposure increased with doses up to the 800 mg cohort without a further increase from 800 to 1,800 mg. No dose limiting toxicities were observed at any dose level. Circulating plasma levels of the HIF-2a transcriptional target erythropoietin rapidly decreased with treatment with PT2385 and remained suppressed. Based on safety, pharmacokinetic and EPO pharmacodynamic data, 800 mg twice per day was selected as the recommended Phase 2 dose. An additional 25 patients were enrolled in an expansion cohort at the recommended Phase 2 dose. Among the 51 patients in total, the most common all-grade adverse events (AEs) were anemia, peripheral edema and fatigue. No cardiovascular AEs were noted. To date, one patient had a complete response, three patients had a partial response, and 16 patients had stable disease for 16 or more weeks. 10% of patients remain in this ongoing clinical trial for at least one year.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|